Dhaka, Oct. 25 -- Cystic fibrosis (CF) is a rare but life-threatening genetic disorder with very low life expectancy. Globally, an estimated 189,000 people are suffering from CF, of whom only 60% are diagnosed and just 27% receive treatment. Trikafta from US-based Vertex Pharmaceuticals, is a breakthrough triple combination therapy for CF containing elexacaftor, tezacaftor, and ivacaftor, which significantly improves survival rates. But, unfortunately, very few patients can have access to this blockbuster drug due to the exorbitant cost.

On this grim backdrop, a group of mums whose children are living with CF have launched a community-run buyers' club to help patients around the world access a new, much affordable generic version of Trik...